GEOVAX, INC.
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
- Conditions
- LeukemiaHematopoietic and Lymphoid System NeoplasmCOVID-19 InfectionLymphomaPlasma Cell Myeloma
- Interventions
- Other: Diagnostic Laboratory Biomarker AnalysisBiological: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04977024
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸SUNY-Stony Brook, Stony Brook, New York, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
- Conditions
- COVID-19 Infection
- Interventions
- Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1Drug: Placebo Administration
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT04639466
- Locations
- 🇺🇸
EmVenio Research, Claremont, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Millennium Clinical Trials, Thousand Oaks, California, United States
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
- Conditions
- Recurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03754933
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Winship Cancer Institute - Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
- Conditions
- HIV-1 Infection
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01378156
- Locations
- 🇺🇸
The University of Alabama at Birmingham Alabama Vaccine Research Clinic, Birmingham, Alabama, United States
🇺🇸AIDS Research Alliance, Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States